Zhongli Cai1, Simmyung Yook1,2, Yijie Lu3, Dane Bergstrom1, Mitchell A Winnik3, Jean-Philippe Pignol4, Raymond M Reilly5,6,7,8. 1. Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, M5S 3M2, Canada. 2. College of Pharmacy, Keimyung University, Daegu, South Korea. 3. Department of Chemistry, University of Toronto, Toronto, Ontario, M5S 3H6, Canada. 4. Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 5. Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, M5S 3M2, Canada. raymond.reilly@utoronto.ca. 6. Department of Medical Imaging, University of Toronto, Toronto, Ontario, M5T 1W7, Canada. raymond.reilly@utoronto.ca. 7. Toronto General Research Institute and Joint Department of Medical Imaging, University Health Network, Toronto, Ontario, M5G 1L7, Canada. raymond.reilly@utoronto.ca. 8. Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St, Toronto, Ontario, M5S 3M2, Canada. raymond.reilly@utoronto.ca.
Abstract
PURPOSE: To compare the effectiveness of trastuzumab-modified gold nanoparticles (AuNP) labeled with 177Lu (trastuzumab-AuNP-177Lu) targeted to HER2 with non-targeted AuNP-177Lu for killing HER2-overexpressing breast cancer (BC) cells in vitro and inhibiting tumor growth in vivo following intratumoral (i.t.) injection. METHODS: AuNP (30 nm) were modified with polyethylene glycol (PEG) polymers linked to trastuzumab or to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelators to complex 177Lu. The binding and internalization of trastuzumab-AuNP-177Lu in HER2-positive SK-BR-3, BT-474 and MDA-MB-361 human BC cells were studied. Clonogenic survival and DNA double-strand breaks (DSBs) were measured after exposure of SK-BR-3 or MDA-MB-361 cells to trastuzumab-AuNP-177Lu or AuNP-177Lu. NOD/SCID mice with s.c. MDA-MB-361 tumor xenografts were treated by i.t. injection of 3 MBq (0.15 mg) of trastuzumab-AuNP-177Lu, AuNP-177Lu or normal saline. Tumor growth was measured over 16 days and normal tissue toxicity evaluated. RESULTS: Trastuzumab-AuNP-177Lu was bound and internalized by HER2 positive BC cells (KD = 7.6 ± 2.0 nM). Trastuzumab-AuNP-177Lu was 42.9 and 2.6-fold more effective than AuNP-177Lu at decreasing the clonogenic survival of SK-BR-3 (1.3 × 106 HER2/cell) and MDA-MB-361 (5.1 × 105 HER2/cell) cells, respectively, exposed overnight to these agents (1.5 nM; 20 MBq/mg Au). Under the same treatment conditions, 10-fold and 2.8-fold more DNA DSBs were observed in SK-BR-3 and MDA-MB-361 cells, respectively, exposed to trastuzumab-AuNP-177Lu than AuNP-177Lu. Trastuzumab-AuNP-177Lu was 1.8-fold more effective at inhibiting tumor growth than AuNP-177Lu. No or minimal normal tissue toxicity was observed for trastuzumab-AuNP-177Lu or AuNP-177Lu treatments. CONCLUSION: Trastuzumab-AuNP-177Lu enables an efficient local radiation treatment of HER2-positive BC.
PURPOSE: To compare the effectiveness of trastuzumab-modified gold nanoparticles (AuNP) labeled with 177Lu (trastuzumab-AuNP-177Lu) targeted to HER2 with non-targeted AuNP-177Lu for killing HER2-overexpressing breast cancer (BC) cells in vitro and inhibiting tumor growth in vivo following intratumoral (i.t.) injection. METHODS:AuNP (30 nm) were modified with polyethylene glycol (PEG) polymers linked to trastuzumab or to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelators to complex 177Lu. The binding and internalization of trastuzumab-AuNP-177Lu in HER2-positive SK-BR-3, BT-474 and MDA-MB-361 human BC cells were studied. Clonogenic survival and DNA double-strand breaks (DSBs) were measured after exposure of SK-BR-3 or MDA-MB-361 cells to trastuzumab-AuNP-177Lu or AuNP-177Lu. NOD/SCIDmice with s.c. MDA-MB-361 tumor xenografts were treated by i.t. injection of 3 MBq (0.15 mg) of trastuzumab-AuNP-177Lu, AuNP-177Lu or normal saline. Tumor growth was measured over 16 days and normal tissue toxicity evaluated. RESULTS:Trastuzumab-AuNP-177Lu was bound and internalized by HER2 positive BC cells (KD = 7.6 ± 2.0 nM). Trastuzumab-AuNP-177Lu was 42.9 and 2.6-fold more effective than AuNP-177Lu at decreasing the clonogenic survival of SK-BR-3 (1.3 × 106 HER2/cell) and MDA-MB-361 (5.1 × 105 HER2/cell) cells, respectively, exposed overnight to these agents (1.5 nM; 20 MBq/mg Au). Under the same treatment conditions, 10-fold and 2.8-fold more DNA DSBs were observed in SK-BR-3 and MDA-MB-361 cells, respectively, exposed to trastuzumab-AuNP-177Lu than AuNP-177Lu. Trastuzumab-AuNP-177Lu was 1.8-fold more effective at inhibiting tumor growth than AuNP-177Lu. No or minimal normal tissue toxicity was observed for trastuzumab-AuNP-177Lu or AuNP-177Lu treatments. CONCLUSION:Trastuzumab-AuNP-177Lu enables an efficient local radiation treatment of HER2-positive BC.
Entities:
Keywords:
HER2; breast cancer; gold nanoparticles; intratumoral injection; lutetium-177
Authors: Sylvia Adams; A Bapsi Chakravarthy; Martin Donach; Darcy Spicer; Stella Lymberis; Baljit Singh; Joshua A Bauer; Tsivia Hochman; Judith D Goldberg; Franco Muggia; Robert J Schneider; Jennifer A Pietenpol; Silvia C Formenti Journal: Breast Cancer Res Treat Date: 2010-09-29 Impact factor: 4.872
Authors: Ravi Shukla; Nripen Chanda; Ajit Zambre; Anandhi Upendran; Kavita Katti; Rajesh R Kulkarni; Satish Kumar Nune; Stan W Casteel; Charles Jeffrey Smith; Jatin Vimal; Evan Boote; J David Robertson; Para Kan; Hendrik Engelbrecht; Lisa D Watkinson; Terry L Carmack; John R Lever; Cathy S Cutler; Charles Caldwell; Raghuraman Kannan; Kattesh V Katti Journal: Proc Natl Acad Sci U S A Date: 2012-07-16 Impact factor: 11.205
Authors: J P Ferrière; I Assier; H Curé; S Charrier; F Kwiatkowski; J L Achard; J Dauplat; P Chollet Journal: Am J Clin Oncol Date: 1998-04 Impact factor: 2.339
Authors: S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto Journal: Lancet Date: 2011-10-19 Impact factor: 79.321
Authors: Nicholas Sobol; Logan Sutherlin; Edyta Cedrowska; Joshua Schorp; Cristina Rodríguez-Rodríguez; Vesna Sossi; Jimmy Lattimer; Douglas C Miller; Paul Pevsner; J David Robertson Journal: APL Bioeng Date: 2017-12-27
Authors: Baljeet Seniwal; Velaphi C Thipe; Sukhvir Singh; Telma C F Fonseca; Lucas Freitas de Freitas Journal: Front Oncol Date: 2021-11-24 Impact factor: 6.244